Literature DB >> 15798777

Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype--phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex.

Ozgur Sancak1, Mark Nellist, Miriam Goedbloed, Peter Elfferich, Cokkie Wouters, Anneke Maat-Kievit, Bernard Zonnenberg, Senno Verhoef, Dicky Halley, Ans van den Ouweland.   

Abstract

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterised by the development of hamartomas in multiple organs and tissues. TSC is caused by mutations in either the TSC1 or TSC2 gene. We searched for mutations in both genes in a cohort of 490 patients diagnosed with or suspected of having TSC using a combination of denaturing gradient gel electrophoresis, single-strand conformational polymorphism, direct sequencing, fluorescent in situ hybridisation and Southern blotting. We identified pathogenic mutations in 362 patients, a mutation detection rate of 74%. Of these 362 patients, 276 had a definite clinical diagnosis of TSC and in these patients 235 mutations were identified, a mutation detection rate of 85%. The ratio of TSC2:TSC1 mutations was 3.4:1. In our cohort, both TSC1 mutations and mutations in familial TSC2 cases were associated with phenotypes less severe than de novo TSC2 mutations. Interestingly, consistent with other studies, the phenotypes of the patients in which no mutation was identified were, overall, less severe than those of patients with either a known TSC1 or TSC2 mutation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15798777     DOI: 10.1038/sj.ejhg.5201402

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  145 in total

Review 1.  Neurocutaneous Disorders for the Practicing Neurologist: a Focused Review.

Authors:  Anna Carolina Paiva Costa T Figueiredo; Nikolas Mata-Machado; Matthew McCoyd; José Biller
Journal:  Curr Neurol Neurosci Rep       Date:  2016-02       Impact factor: 5.081

Review 2.  Positive and negative regulation of TSC2 activity and its effects on downstream effectors of the mTOR pathway.

Authors:  Jaroslaw Jozwiak; Sergiusz Jozwiak; Tomasz Grzela; Maciej Lazarczyk
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

3.  Subependymal giant cell astrocytoma and concordant expression in a disease of variable penetrance.

Authors:  Rob D Dickerman; Anders Cohen
Journal:  Neurosurg Rev       Date:  2005-07-22       Impact factor: 3.042

4.  Characterisation of TSC1 promoter deletions in tuberous sclerosis complex patients.

Authors:  Ans M W van den Ouweland; Peter Elfferich; Bernard A Zonnenberg; Willem F Arts; Tjitske Kleefstra; Mark D Nellist; Jose M Millan; Caroline Withagen-Hermans; Anneke J A Maat-Kievit; Dicky J J Halley
Journal:  Eur J Hum Genet       Date:  2010-09-29       Impact factor: 4.246

5.  Clinical utility gene card for: tuberous sclerosis complex (TSC1, TSC2).

Authors:  Karin Mayer; Christa Fonatsch; Katharina Wimmer; Ans M W van den Ouweland; Anneke J A Maat-Kievit
Journal:  Eur J Hum Genet       Date:  2013-06-12       Impact factor: 4.246

6.  Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome.

Authors:  Mark B Consugar; Wai C Wong; Patrick A Lundquist; Sandro Rossetti; Vickie J Kubly; Denise L Walker; Laureano J Rangel; Richard Aspinwall; W Patrick Niaudet; Seza Ozen; Albert David; Milen Velinov; Eric J Bergstralh; Kyongtae T Bae; Arlene B Chapman; Lisa M Guay-Woodford; Jared J Grantham; Vicente E Torres; Julian R Sampson; Brian D Dawson; Peter C Harris
Journal:  Kidney Int       Date:  2008-09-24       Impact factor: 10.612

7.  Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis.

Authors:  Dan Ehninger; Sangyeul Han; Carrie Shilyansky; Yu Zhou; Weidong Li; David J Kwiatkowski; Vijaya Ramesh; Alcino J Silva
Journal:  Nat Med       Date:  2008-06-22       Impact factor: 53.440

Review 8.  Tuberous sclerosis complex: a brave new world?

Authors:  Kevin C Ess
Journal:  Curr Opin Neurol       Date:  2010-04       Impact factor: 5.710

9.  A reliable cell-based assay for testing unclassified TSC2 gene variants.

Authors:  Ricardo Coevoets; Sermin Arican; Marianne Hoogeveen-Westerveld; Erik Simons; Ans van den Ouweland; Dicky Halley; Mark Nellist
Journal:  Eur J Hum Genet       Date:  2008-10-15       Impact factor: 4.246

Review 10.  Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.

Authors:  Jeffrey P MacKeigan; Darcy A Krueger
Journal:  Neuro Oncol       Date:  2015-08-19       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.